Showing results (101-110 of 106) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Journal of Medicinal Chemistry|December 4, 2009
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonistRichard A Hartz, Vijay T Ahuja, Xiaoliang Zhuo, et al.Bioorganic & Medicinal Chemistry Letters|September 27, 2012
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agentsJeffrey A Deskus, Douglas D Dischino, Ronald J Mattson, et al.Journal of Medicinal Chemistry|June 26, 2009
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonistsRichard A Hartz, Vijay T Ahuja, Argyrios G Arvanitis, et al.Cancer Cell|October 18, 2024
Integrating priorities at the intersection of cancer and neuroscienceWilliam L Hwang, Ella N Perrault, Alexander Birbrair, et al.Research Square|July 28, 2023
Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockadeErez N Baruch, Priyadahrshini Nagarajan, Frederico O Gleber-Netto, et al.Nature|August 20, 2025
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapyErez N Baruch, Frederico O Gleber-Netto, Priyadharsini Nagarajan, et al.Pageof 11